clinical trial · NCT00200356

Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

Tanabe Pharma Corp →·phase4·completed·n = 401

Cerebral InfarctionEdaravoneSodium Ozagrel

brief summary

This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.

started

Aug 1, 2004

primary completion

—

completion

Oct 1, 2006

last updated

Jan 7, 2026

official title

Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol